FR940722-0-00037 FR940722-0-00010 21 CFR Part 343 [Docket No. 94N&hyph;0255] Over-the-Counter Marketing of Internal Analgesic, Antipyretic, and Antirheumatic Drug Products; Background Document for Advisory Committee Meeting; Availability; Establishment of a Public Docket and Request for Comments AGENCY: Food and Drug Administration, HHS. ACTION: Availability of background document; establishment of a public docket and request for comments. SUMMARY: The Food and Drug Administration is announcing the availability of a background document for the joint meeting of the Nonprescription Drugs Advisory Committee and the Arthritis Advisory Committee on effectiveness data requirements and labeling for over-the-counter (OTC) marketing of internal analgesic, antipyretic and antirheumatic drug products scheduled for September 8 and 9, 1994. The background information is being made available to ensure that all interested parties are aware of the issues that are the subject of the committee discussion. FDA is also announcing that it is establishing a public docket for comments, views, and other information submitted to the agency on these subjects from interested persons. DATES: Submit written comments by August 15, 1994 , in order for written comments to be considered for discussion at the September 8 and 9, 1994, advisory committee meeting. ADDRESSES: Submit written comments or relevant data and requests for single copies of the background document to the Dockets Management Branch (HFA&hyph;305), Food and Drug Administration, rm. 1&hyph;23, 12420 Parklawn Dr., Rockville, MD 20857. Comments and requests should be identified with the docket number found in the brackets in the heading of this document. Send two self-addressed adhesive labels to assist the branch in processing your requests. Three copies of written comments should be submitted, except that individuals may submit one copy. The background document and received comments are available for public examination at the Dockets Management Branch (address above), between 9 a.m. and 4 p.m., Monday through Friday. FOR FURTHER INFORMATION CONTACT: Lee L. Zwanziger, Center for Drug Evaluation and Research (HFD&hyph;9), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301&hyph;443&hyph;4695. SUPPLEMENTARY INFORMATION: In the Federal Register of July 11, 1994 (59 FR 35375), FDA announced that a forthcoming joint meeting of the Nonprescription Drugs Advisory Committee and the Arthritis Advisory Committee on effectiveness data requirements and labeling for over-the-counter (OTC) marketing of internal analgesic, antipyretic and antirheumatic drug products will be held on September 8 and 9, 1994. FDA is holding this meeting to discuss: (1) Data requirements to support specific types of indications for OTC analgesic drug products; (2) Recommendations for labeling indications for OTC analgesics; and (3) The current state of scientific knowledge in the areas of pain receptors, mechanism(s) of pain perception, and the basis for response to analgesic drug classes. The purpose of this meeting is to address specific topics and questions contained in the background document that could result in future rulemaking. FDA has established public docket No. 94N&hyph;0255 to enable interested persons to submit comments or other relevant data on the background document. Dated: July 15, 1994. Michael R. Taylor, Deputy Commissioner for Policy. [FR Doc. 94&hyph;17811 Filed 7&hyph;21&hyph;94; 8:45 am] BILLING CODE 4160&hyph;01&hyph;F
